Published in Nat Rev Gastroenterol Hepatol on April 01, 2009
Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2013) 2.43
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Liver and diabetes. A vicious circle. Hepatol Res (2013) 1.10
Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol (2012) 1.05
Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol (2014) 1.05
Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol (2014) 1.04
Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol (2009) 1.01
NAFLD, Estrogens, and Physical Exercise: The Animal Model. J Nutr Metab (2011) 0.97
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol (2014) 0.94
Chromosome 19 open reading frame 80 is upregulated by thyroid hormone and modulates autophagy and lipid metabolism. Autophagy (2013) 0.88
Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol (2010) 0.85
Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2016) 0.80
Cross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatment. World J Gastroenterol (2013) 0.79
Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr Disord (2015) 0.78
Proteomic analysis of the palmitate-induced myotube secretome reveals involvement of the annexin A1-formyl peptide receptor 2 (FPR2) pathway in insulin resistance. Mol Cell Proteomics (2015) 0.78
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The "Musketeer" in the Spotlight. Int J Mol Sci (2016) 0.76
Lipid profiling and transcriptomic analysis reveals a functional interplay between estradiol and growth hormone in liver. PLoS One (2014) 0.76
Estrogens regulate the hepatic effects of growth hormone, a hormonal interplay with multiple fates. Front Endocrinol (Lausanne) (2013) 0.76
Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? Int J Mol Sci (2016) 0.76
Non-alcoholic fatty liver disease connections with fat-free tissues: A focus on bone and skeletal muscle. World J Gastroenterol (2017) 0.75
Occult endocrine dysfunction in patients with cirrhosis of liver. J Family Med Prim Care (2017) 0.75
Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma. Sci Rep (2016) 0.75
Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis. J Clin Transl Hepatol (2017) 0.75
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. Int J Mol Sci (2017) 0.75
[Non-alcoholic steatohepatitis and cirrhosis in young adult patients with hypothalamic-pituitary dysfunction]. Pathologe (2013) 0.75
Apoptosis in the pathogenesis and treatment of disease. Science (1995) 20.24
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod (2004) 12.27
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Clinical hepatology: profile of an urban, hospital-based practice. Hepatology (1996) 2.56
Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 2.52
Thyroid disease and lipids. Thyroid (2002) 2.40
'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol (2006) 2.03
The relationship between the thyroid gland and the liver. QJM (2002) 2.03
Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl (2004) 1.96
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology (2006) 1.85
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol (2007) 1.78
The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med (2005) 1.75
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med (1998) 1.70
Adrenal insufficiency in liver disease - what is the evidence? J Hepatol (2007) 1.69
Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am (2007) 1.63
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol (2007) 1.55
Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab (2007) 1.49
Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism (2003) 1.47
Growth hormone and the metabolic syndrome. J Endocrinol Invest (1999) 1.44
Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid (1997) 1.43
Bile acids and the membrane bile acid receptor TGR5--connecting nutrition and metabolism. Thyroid (2008) 1.40
Methimazole alleviates hepatic encephalopathy in bile-duct ligated cirrhotic rats. J Chin Med Assoc (2006) 1.40
Unexplained hypertransaminasaemia: clue to diagnosis of Addison's disease. Eur J Gastroenterol Hepatol (2002) 1.40
Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol (2007) 1.39
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol (2007) 1.39
The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol (2004) 1.36
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Thyroid hormone-induced oxidative stress. Cell Mol Life Sci (2006) 1.32
Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol (1994) 1.25
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem (2004) 1.24
Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr (2001) 1.23
Thyroid disorders in chronic hepatitis C virus infection. Thyroid (2006) 1.21
Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. Physiol Genomics (2007) 1.20
Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.20
Methimazole-induced hepatotoxicity. Endocr Pract (2002) 1.19
The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology (2002) 1.19
Thyroid hormone effects on mitochondrial energetics. Thyroid (2008) 1.18
Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 1.18
Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology (2006) 1.15
Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut (2003) 1.15
Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol (2003) 1.14
Two cases of thyroid storm-associated cholestatic jaundice. Endocr Pract (2007) 1.14
Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology (2006) 1.13
Peripheral metabolism of thyroid hormone and glucose homeostasis. Thyroid (2005) 1.12
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology (2005) 1.12
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal. Nat Clin Pract Endocrinol Metab (2008) 1.12
Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 1.11
Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) (2001) 1.10
Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab (2004) 1.10
Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 1.09
Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocr J (2006) 1.07
Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology (2008) 1.06
Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials (2008) 1.05
Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clin Endocrinol (Oxf) (2007) 1.05
Addison's disease - a review of some clinical, pathological and immunological features. Dan Med Bull (1974) 1.05
Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone. Endocrinology (2006) 1.03
Mechanism of the development of obesity in animals with hypothalamic lesions. Physiol Rev (1946) 1.03
Severe hyperthyroidism induces mitochondria-mediated apoptosis in rat liver. Hepatology (2004) 1.03
Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03
Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynaecol Res (2008) 1.02
Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol (Oxf) (2008) 1.01
Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab (2007) 1.01
Cross-talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thyroid hormone resistance mouse model. J Biol Chem (2005) 1.00
Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol (2008) 0.98
Bile flow to the duodenum is reduced in hypothyreosis and enhanced in hyperthyreosis. Neurogastroenterol Motil (2002) 0.98
Association between thyroid function and gallstone disease. World J Gastroenterol (2005) 0.97
Myxedema ascites: case report and literature review. J Korean Med Sci (2006) 0.96
Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 0.95
Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology (2005) 0.95
Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf) (2007) 0.95
"Let there be bile"--understanding hepatic injury in cholestasis. J Pediatr Gastroenterol Nutr (2006) 0.94
Liver changes in patients with hyperthyroidism. Liver (1991) 0.94
Intrahepatic cholestasis in subclinical and overt hyperthyroidism: two case reports. J Med Case Rep (2008) 0.92
Liver involvement in Addison's disease. Am J Gastroenterol (1990) 0.92
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J Pharmacol Exp Ther (2005) 0.92
Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest (2008) 0.92
Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 0.92
Induced hypothyroidism accelerates the regression of liver fibrosis in rats. J Gastroenterol Hepatol (2007) 0.91
Liver involvement and abnormal iron variables in undiagnosed Addison's disease. Endocr Pract (2001) 0.91
Subclinical Addison's disease: a cause of persistent abnormalities in transaminase values. Gastroenterology (1995) 0.91
Should nonalcoholic fatty liver disease be renamed? Dig Dis (2005) 0.89
Effect of growth hormone on fatty liver in panhypopituitarism. Arch Dis Child (1997) 0.89
Involvement of high density lipoprotein as substrate cholesterol for steroidogenesis by bovine adrenal fasciculo-reticularis cells. Life Sci (1998) 0.88
Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol (2008) 0.88
Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril (2005) 0.87
Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology (2001) 0.86
Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol (2006) 0.86
Influence of small-bowel transit time on dietary cholesterol absorption in human beings. N Engl J Med (1982) 0.85
Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod (2005) 0.85
Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit (2001) 0.85
Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract (2005) 0.84
Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol (2008) 0.84
Polycystic ovary syndrome: diagnosis and treatment. Am J Med (2007) 0.84
Growth hormone plasma levels in nonalcoholic fatty liver disease. Am J Gastroenterol (2002) 0.83
A case of polyglandular autoimmune syndrome type III complicated with autoimmune hepatitis. Endocr J (2006) 0.83
Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection. Br J Rheumatol (1998) 0.83
The effects of hypothyroidism on liver status of cirrhotic patients. J Clin Gastroenterol (2000) 0.82
Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol (2009) 2.75
Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis (2012) 1.79
From NAFLD in clinical practice to answers from guidelines. J Hepatol (2013) 1.76
ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. Dig Liver Dis (2012) 1.62
Changes in bile acid synthesis in gallstone disease: cause, consequence, or neither? Hepatology (2007) 1.40
Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci (2003) 1.37
Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. J Clin Endocrinol Metab (2003) 1.17
Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol (2005) 1.16
Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int (2012) 1.11
Liver and diabetes. A vicious circle. Hepatol Res (2013) 1.10
Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol (2005) 1.10
Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol (2015) 1.08
Fatty liver, carotid disease and gallstones: a study of age-related associations. World J Gastroenterol (2006) 1.03
Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) (2008) 0.98
Statins in liver disease: a molehill, an iceberg, or neither? Hepatology (2008) 0.96
Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials (2006) 0.95
Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med (2011) 0.95
Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol (2011) 0.92
Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother (2011) 0.90
Gender, fatty liver and GGT. Hepatology (2006) 0.89
Should nonalcoholic fatty liver disease be renamed? Dig Dis (2005) 0.89
Acute abdomen associated with schistosomiasis of the appendix. Dig Dis Sci (2006) 0.87
Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol (2009) 0.86
Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology (2003) 0.85
Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clin Res Hepatol Gastroenterol (2012) 0.84
The hepatitis C virus-associated dysmetabolic syndrome. Hepatology (2008) 0.84
Growth hormone plasma levels in nonalcoholic fatty liver disease. Am J Gastroenterol (2002) 0.83
Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. Metab Syndr Relat Disord (2013) 0.83
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res (2011) 0.82
Nonalcoholic fatty liver disease induced by leuprorelin acetate. J Clin Gastroenterol (2008) 0.81
Risk of birth defects associated with maternal pregestational diabetes. Eur J Epidemiol (2014) 0.81
Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. Arch Med Res (2012) 0.80
Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. Dig Liver Dis (2012) 0.80
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 0.79
Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. Biochim Biophys Acta (2002) 0.79
Meal-induced blood pressure variation and cardiovascular mortality in ambulatory hypertensive elderly patients: preliminary results. J Hypertens (2012) 0.79
Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia? Intern Emerg Med (2008) 0.79
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. Steroids (2008) 0.78
Statins and HCV: a complex issue. Hepatology (2007) 0.78
Pediatric gallstone disease in familial hypobetalipoproteinemia. J Hepatol (2005) 0.77
The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology. Hepatology (2008) 0.77
Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. Medicine (Baltimore) (2016) 0.77
Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree? Hepatology (2011) 0.76
Fatty liver and carotid intimal thickening: a tale of two ages? Am J Gastroenterol (2009) 0.75
Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology (2002) 0.75
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 0.75
NAFLD and cardiovascular risk: direct evidence for the tale of two ages. Am J Gastroenterol (2009) 0.75
17 Beta-estradiol prevents cytotoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures. J Gastroenterol Hepatol (2006) 0.75
Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2010) 0.75
[Cholestatic icterus: is there still a role for the clinic?]. Ann Ital Med Int (2004) 0.75
Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. AIDS (2017) 0.75
Olanzapine metabolic side effects: a weight gain issue? Intern Emerg Med (2008) 0.75
In vivo degradation of cholesterol to bile acids is reduced in patients receiving parenteral nutrition. JPEN J Parenter Enteral Nutr (2013) 0.75
[Multifactorial hepatopathy in a patient with biliopancreatic diversion]. Ann Ital Med Int (2003) 0.75